We write to express our strong opposition to portions of the recently released 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule. Specifically, we are concerned that this proposed rule would reverse a patient–friendly policy about how health plans treat cost–sharing assistance and make it even harder for patients to afford their medicines. While we value your partnership and interest in addressing high drug pricing, we believe the provisions in the proposed rule would put life–saving medications out of the hands of patients who need them.
Categories
- Access
- Advocacy
- California
- Coalitions
- Comment Letters
- Copay Accumulators
- Copay Assistance
- COVID-19
- Drug Costs
- FDA
- Featured
- Featured Action
- Federal Issues
- Health Insurance
- Health Policy
- ICER
- Illinois
- Issues
- Letters Submitted
- Letters Supported
- Massachusetts
- Medicaid
- Medicare
- Medicare Part D
- News
- Op-Ed
- Out of Pocket Costs
- Pharmacy Benefit Managers
- Podcast
- Prescription Drugs
- Press Releases
- Public Statement
- QALY
- State Issues
- Statements
- Step Therapy
- Surprise Billing
- Uncategorized
- Value Based Insurance Design
- Value Frameworks
- Virtual Advocacy Chat
Tags
21st Century Cures Act
340B
Access to Care
Advocacy
Alzheimer's
Biden Administration
biosimilars
Cancer
cms
Copay Accumulators
copay assistance
COVID-19 Vaccine
drug costs
Drug Manufacturing
Drug Pricing
drug rebate
fail first
FDA
Gene Therapies
H.R.3
Health Insurance
hospital bills
HR 3708
hsa
ICER
Insurance design
Joe Biden
medicare Part B
medicare part D
Mental Health
Nonmedical Switching
open enrollment
Out of Pocket Costs
PBM
PBMs
pharmacy benefit managers
Price Transparency
Prior Authorization
QALY
Rare Disease
Right to Repair
Step Therapy
Telehealth
transparency
Value Framework